Get started

Healthcare

Nasdaq Healthcare: Trend is defined If you like this idea, don't forget to hit the Like Button! After the rally that started at the beginning of October, the Nasdaq Healthcare Index trend is still defined, and it is approaching a new phase after a short term retracement. Values above the Ichimoku Green Cloud confirm bullish power. Next days' trading sessions will be useful to understand if IXHC will maintain the support at 911.60 and continue its long term positive trend. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
NASDAQ:IXHCLong
by Investing_Fellow
Alexion: Trading around Volume Profile POCIf you like this idea, don't forget to hit the Like Button! Alexion business depends on patent-protected therapies in ultrarare and rare diseases of high unmet medical needs. While competitors are entering the market with biosimilars, Alexion still maintains an essential share of the market. My long term view is bullish. However, from a technical point of view, we are in a critical consolidation phase that started at the end of October 2019. The stock price is consolidating around $107.88 level. What to do now? I would wait for Alexion to exit the consolidation phase with a breakout. My signal is the break of the $116.61 important resistance. Look at the purple line in the graph (Developing POC) to monitor interesting volumes movements able to push up the price (in the chart Developing POC is overlapping the POC red line). I suggest to not go in with a trade immediately after the resistance breakout since Alexion presents high uncertainty. Thus wait for a confirmation green candle (daily). Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
A
by Investing_Fellow
What's The Next Move For DARE? Big news from Bayer and Dare today . Next thing to watch is for FDA approval and then if/when commercialization begins. Until then I think it's still very speculative. HOWEVER. important to note the chart. Last time it traded this high, it remained the case for a few weeks and then plummeted back down to earth. The last time it consistently traded around this price was way back in 2018. So could this mark a new, higher channel or another head fake? "However, the fact remains that a commercialized drug in connection with a company like Bayer isn’t something to ignore. Dare could be entitled to as much as $310 million in milestone payments plus a tiered royalty structure. Does this make it one of the penny stocks to buy right now? That will be determined by the market reaction throughout the week, in my opinion. For now, at least, it seems like one of the penny stocks to watch to start the week." Quote SOURCE: Best Penny Stocks To Watch This Week? 1 Up Over 210% This Year DARE , OTC:BAYRY
NASDAQ:DARE
by PennyStocks101
Intuitive Surgical: expensive and to exit consolidationIntuitive Surgical produces robotic-assisted surgical systems. Currently, the company holds a significant market share in urology and gynecology areas. However, the business model is predicted to expand to other areas such as thoracic, colorectal, and other general soft tissue procedures. From a technical point of view, the stock recovered the highs registered in April 2019, retracing on the last day of trading to the $581 level. However, the price was not able to overtake the $600 resistance that I consider essential in that case. The last session closed above the green Ichimoku Cloud; however, I see the price too close to the cloud support at $572.71. An important signal comes from the Chikou Span (Lagging Span) of the Ichimoku Clouds. The "lagging span" is created by plotting closing prices 26 periods behind the latest closing price of an asset. Usually, when the price is above the line, it could be an indication of weakness (price too high). On the other hand, when the price is below the Chikou span, it could be an indication of strength (price too low). I highlighted in the graph the relationship between the Chikou Span and the current price. The last close perfectly matched the Lagging Span price. Besides, I believe that the market overvalues the company. The stock is currently trading above its normal Price/EBITDA ratio of 32.75, at 50.13 (I used ten years of data). Probably the stock is too expensive. My strategy is to wait until the green support of the green cloud (orange in the chart) is broken. To be sure of the beginning of a downtrend, however, wait until the red support of the green cloud is overtaken (purple in the chart). Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
NASDAQ:ISRGShort
by Investing_Fellow
Biogen: Further GrowthAfter the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase. I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an exciting phase, testing the high line of the cloud with a bullish configuration, as also confirmed by the Stochastic. The upward trend is also confirmed by fundamental analysis. Biogen counts on a strong collaboration with Roche in oncology, and on growing revenues thanks to Ocrevus (Multiple Sclerosis), as well as to a significant pipeline. Furthermore, the complexity of Biogen's drugs makes the production of Biosimilars difficult. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:BIIBLong
by Investing_Fellow
MYL - Worth Keeping on a Watch ListThe weekly chart for Mylan has broken out from a bearish trendline this week. We can see from the VPVR that there is not much volume resistance at these prices either. There is also a bullish divergence on the RSI. Relative strength has begun to improve too. The price still needs to clear both a 50-EMA & 200-EMA & bulls would want to see a golden cross occur in the future. A lot of hurdles left for this stock to get over but this may be a name worth keeping on a watch list at least.
MLong
by Chartimistic
HIIQ an undervalued growth stock in a sector with political riskHIIQ was already undervalued, with a forward P/E of 4.65, but it just got even moreso today as analysts bumped its earnings forecast by roughly 20%. This is a low-volume stock, so the market hasn't yet noticed or reacted to the upgrade except for a few options traders. The main problem with HIIQ is that health insurance stocks face a lot of political risk going into an election year when the Democratic candidates may be inclined to try to kill this industry altogether.
HLong
by ChristopherCarrollSmith
Convatec - Chronically undervalued?Buy Convatec (CTEC.L) ConvaTec Group PLC is a United Kingdom-based medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. Market Cap: £3.79Billion The recovery over the medium term continues as the shares trade in a sequence of higher highs and higher lows. The recent corrective move back to the trend line has attracted some buying interest. The formation and break of a small wedge is also an encouraging sign that we can expect a continuation. There is an unfilled gap at 223p to target on the upside. Stop: 181.6p Target 1: 211p Target 2: 222p Target 3: 240p Interested in UK Stocks? Join our free Telegram channel for up to date analysis on the best main market opportunities in the UK right now - t.me
LSE:CTECLong
by Investamate
CVS moment of truth is comingCVS has been headed toward the top of its parallel channel. It's currently overbought, so its first test of the channel top may get rejected. However, expect a breakout soon after. CVS is my favorite investment thesis in the entire market right now. The company is opening 1500 HealthHub stores by the end of 2021 and is also completing a merger with Aetna. Its earnings are expected to grow, and the stock is absurdly undervalued. Fair value based on forward P/E for 2021 is something like $95 per share. Even based on this year's P/E, it should be at least $79. (I base these numbers on the Zack's "Price and Consensus" chart, which is one of my favorite tools for fundamental analysis. We'll do an educational episode on this on the "Wall Street Petting Zoo" Youtube channel next week.)
NYSE:CVSLong
by ChristopherCarrollSmith